Ogurtsova K, da Rocha Fernandes JD, Huang Y et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.
CAS
Article
Google Scholar
de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–9.
Article
Google Scholar
Magee C, Grieve DJ, Watson CJ, Brazil DP. Diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther. 2017;31:579–92.
Article
Google Scholar
Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2015;66:S1–305.
Article
Google Scholar
Chan GC, Tang SC. Diabetic nephropathy: landmark clinical trials and tribulations. Nephrol Dial Transplant. 2016;31:359–68.
CAS
Article
Google Scholar
Tonna S, El-Osta A, Cooper ME, Tikellis C. Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol. 2010;6:332–41.
CAS
Article
Google Scholar
Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–9.
Article
Google Scholar
Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users’ guides to the medical literature: 25. Evidence-based medicine: principles for applying the Users’ Guides to patient care. Evidence-Based Medicine Working Group. JAMA. 2000;284:1290–6.
CAS
Article
Google Scholar
Hudson KL, Lauer MS, Collins FS. Toward a new era of trust and transparency in clinical trials. JAMA. 2016;316:1353–4.
Article
Google Scholar
Johnson RT, Dickersin K. Publication bias against negative results from clinical trials: three of the seven deadly sins. Nat Clin Pract Neurol. 2007;3:590–1.
Article
Google Scholar
Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov—the final rule. N Engl J Med. 2016;375:1998–2004.
Article
Google Scholar
Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58:729–36.
CAS
Article
Google Scholar
Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978–86.
CAS
Article
Google Scholar
Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013;62:3224–31.
CAS
Article
Google Scholar
Ott C, Schneider MP, Delles C, Schlaich MP, Schmieder RE. Reduction in basal nitric oxide activity causes albuminuria. Diabetes. 2011;60:572–6.
CAS
Article
Google Scholar
Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61.
CAS
Article
Google Scholar
Anantharaman R, Bhansali A, Bhadada SK, et al. A pilot study on the effect of telmisartan and ramipril on 24 h blood pressure profile and dipping pattern in type 1 diabetes patients with nephropathy. Indian J Med Res. 2011;134:658–63.
CAS
Article
Google Scholar
Dailey GE, Boden GH, Creech RH, et al. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism. 2000;49:1491–5.
CAS
Article
Google Scholar
Miller ER 3rd, Juraschek SP, Anderson CA et al. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. Diabetes Care. 2013;36:1462–9.
CAS
Article
Google Scholar
Lundwall K, Jorneskog G, Jacobson SH, Spaak J. Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial. Am J Nephrol. 2015;42:265–73.
CAS
Article
Google Scholar
Miraghajani MS, Esmaillzadeh A, Najafabadi MM, Mirlohi M, Azadbakht L. Soy milk consumption, inflammation, coagulation, and oxidative stress among type 2 diabetic patients with nephropathy. Diabetes Care. 2012;35:1981–5.
CAS
Article
Google Scholar
Ott C, Kistner I, Keller M, et al. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia. 2016;59:2579–87.
CAS
Article
Google Scholar
Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Investig. 2008;68:731–8.
CAS
Article
Google Scholar
Jimenez-Osorio AS, Garcia-Nino WR, Gonzalez-Reyes S, et al. The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J Ren Nutr. 2016;26:237–44.
CAS
Article
Google Scholar
Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.
CAS
Article
Google Scholar
Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17.
CAS
Article
Google Scholar
Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58:776–83.
CAS
Article
Google Scholar
McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36:237–44.
CAS
Article
Google Scholar
Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015;17:152–60.
CAS
Article
Google Scholar
Laakso M, Rosenstock J, Groop PH, et al. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care. 2015;38:e15–7.
CAS
Article
Google Scholar
Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59:1860–70.
CAS
Article
Google Scholar
Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194–207.
CAS
Article
Google Scholar
Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999;34:795–808.
CAS
Article
Google Scholar
Lampert A, Hoffmann GF, Ries M. Ten years after the International Committee of Medical Journal Editors’ Clinical Trial Registration Initiative, one quarter of phase 3 pediatric epilepsy clinical trials still remain unpublished: a cross sectional analysis. PLoS ONE. 2016;11:e0144973.
Article
Google Scholar
Mechler K, Hoffmann GF, Dittmann RW, Ries M. Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished—a cross-sectional analysis. Int J Methods Psychiatr Res. 2017;26(4). doi: https://doi.org/10.1002/mpr.1546.
Breil T, Boettcher M, Hoffmann GF, Ries M. Publication status of completed registered studies in paediatric appendicitis: a cross-sectional analysis. BMJ Open. 2018;8:e021684.
Article
Google Scholar
Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results Follow-up of applications submitted to two institutional review boards. JAMA. 1992;267:374–8.
CAS
Article
Google Scholar
Gyawali B, Shimokata T, Honda K, Ando Y. Reporting harms more transparently in trials of cancer drugs. BMJ. 2018;363:k4383.
Article
Google Scholar
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5:49–56.
PubMed
Google Scholar
Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia. 2010;53:49–57.
CAS
Article
Google Scholar
Seegmiller JC, Burns BE, Schinstock CA, Lieske JC, Larson TS. Discordance between iothalamate and iohexol urinary clearances. Am J Kidney Dis. 2016;67:49–55.
CAS
Article
Google Scholar
de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366–76.
Article
Google Scholar
Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.
Article
Google Scholar
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.
CAS
Article
Google Scholar
Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455–63.
CAS
Article
Google Scholar
Montero RM, Covic A, Gnudi L, Goldsmith D. Diabetic nephropathy: what does the future hold? Int Urol Nephrol. 2016;48:99–113.
CAS
Article
Google Scholar
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.
CAS
Article
Google Scholar
Lacava V, Pellicano V, Ferrajolo C, et al. Novel avenues for treating diabetic nephropathy: new investigational drugs. Expert Opin Investig Drugs. 2017;26:445–62.
CAS
Article
Google Scholar